Zai Lab EBITDA Margin 2016-2022 | ZLAB
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Zai Lab (ZLAB) over the last 10 years. The current EBITDA margin for Zai Lab as of March 31, 2022 is .
| Zai Lab EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.17B |
$-0.55B |
-319.88% |
| 2021-12-31 |
$0.14B |
$-0.70B |
-482.64% |
| 2021-09-30 |
$0.12B |
$-0.57B |
-496.52% |
| 2021-06-30 |
$0.09B |
$-0.56B |
-648.28% |
| 2021-03-31 |
$0.06B |
$-0.44B |
-758.62% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.927B |
$0.144B |
|
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
|
